PF3D7_1470900

PF3D7_1470900 encodes the β2 catalytic subunit of the Plasmodium falciparum 20S proteasome core, contributing one of the proteolytic active sites of the parasite's catalytic core particle (PMID:26863983). Cryo-EM structure determination of the Pf20S bound to a β2-selective inhibitor, together with fluorogenic substrate profiling, established that the β2 active site is unusually open relative to its human counterpart and displays parasite-specific amino-acid preferences, providing a structural basis for selective pharmacological targeting (PMID:26863983). Subsequent high-resolution structures of Pf20S–inhibitor complexes showed direct engagement of the β2 subunit by the tripeptide vinyl sulfone WLW-vs and by TDI-8304, which occupy both β2 and β5 active sites, with resistance-mutant (β6 A117D) backgrounds confirming the molecular basis of β2 active-site binding (PMID:38097652). The β2-containing catalytic core assembles into the intact Pf20S particle that is regulated by asymmetric binding of the PfPA28 cap complex, which engages the core on only one side (PMID:31384003), and structural comparisons of the Pf20S core with the human constitutive 20S define the active-site features underlying species-selective inhibition (PMID:34548400). Beyond its identity as the β2 catalytic subunit of the Pf20S core, its regulation, and its role as a selective drug target, no further mechanistic detail specific to PF3D7_1470900 has been characterized in the available corpus.

1. 2016 High

   It was unknown whether the P. falciparum proteasome β2 active site differed enough from the human enzyme to permit selective targeting; solving the Pf20S structure with a β2-selective inhibitor and profiling its substrate preferences established both a distinct active-site architecture and druggable parasite specificity.

   Evidence Cryo-EM single-particle analysis at 3.6 Å with bound β2-selective inhibitor, fluorogenic peptide substrate profiling, and in vitro inhibition assays in P. falciparum

   PMID:26863983

   Open questions at the time

   • Does not resolve the cellular consequences of selective β2 inhibition in the parasite
   • Does not define how the β2 subunit is assembled or matured within the core
2. 2019 High

   The regulatory context of the β2-containing catalytic core was unclear; structures of Pf20S bound to the PfPA28 cap revealed that this activator engages the core asymmetrically, defining how the intact particle is regulated.

   Evidence Single-particle cryo-EM of singly- and doubly-capped Pf20S–PfPA28 complexes (3.8–3.9 Å), crystal structure of PfPA28, molecular dynamics, and genetic deletion of PA28 in P. falciparum

   PMID:31384003

   Open questions at the time

   • Does not isolate a β2-specific functional role within the capped complex
   • Consequences of PA28 binding for β2 catalytic activity not defined
3. 2021 Medium

   It was unclear which active-site features underlie species selectivity of proteasome inhibitors; comparative cryo-EM of Pf20S versus the human constitutive 20S with β5-selective inhibitors provided atomic context for the β2-containing core.

   Evidence Cryo-EM of Pf20S and Hs20Sc with inhibitors, in vitro proteasome activity assays, P. falciparum growth inhibition, and a SCID mouse in vivo model

   PMID:34548400

   Open questions at the time

   • β2 contribution inferred from structural context; the study primarily characterizes β5
   • No direct β2-specific functional readout
4. 2023 High

   The molecular basis for β2 engagement by dual-site inhibitors was undefined; high-resolution structures of wild-type and resistance-mutant Pf20S showed WLW-vs and TDI-8304 binding both β2 and β5, establishing how these inhibitors occupy the β2 active site.

   Evidence High-resolution cryo-EM of Pf20S–inhibitor complexes including the Pf20Sβ6A117D resistance mutant, with resistance selection and mutant characterization in P. falciparum

   PMID:38097652

   Open questions at the time

   • Does not quantify the relative contribution of β2 versus β5 inhibition to parasite killing
   • Does not address β2-specific resistance liabilities

• The distinct cellular substrates and non-structural functional role of the β2 subunit within parasite protein homeostasis remain undefined.
• No physiological substrates specific to the β2 active site identified
• No genetic characterization of β2 subunit essentiality or assembly requirements
• Contribution of β2 catalysis relative to other catalytic subunits in vivo not established